Sildenafil Citrate in Waldenstrom's Macroglobulinemia
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to determine the effects (good or bad) that sildenafil (Viagra) has on patients with slow growing Waldenstrom's macroglobulinemia (WM). Sildenafil blocks the function of several proteins necessary to the survival of certain types of cancer and laboratory tests have shown that it can destroy WM cells.
Condition or disease
Drug: Sildenafil citrate (Viagra)
Sildenafil will be given orally (at home) at a reduced dose for the first week, then each week for 3 more weeks, the dose will be increased. If the patient has no major side effects, then they will receive the maximal dose for 2 years. If they have major side effects, then the dose of the drug might be lowered or the drug stopped.
Sildenafil will be continued until their is disease progression or serious side effects.
While patients are receiving sildenafil, they will be seen in the clinic on months 1,2,9,15 and 21 for blood tests and a subject questionnaire. They will also be seen on months 3,6,12,18 and 24 for a physical exam, blood test, physical assessment test, CT scans of chest, abdomen and pelvis, and a subject questionnaire.
At the end of the study (month 24) a physical exam, blood tests, physical assessment test and a questionnaire will be conducted.
Follow-up includes clinic visits at month 27,33,39 and 45 for blood tests and a questionnaire as well as visits at month 30,36,42 and 48 for physical exam, blood tests, physical assessment test, bone marrow aspirate and biopsy, CT scans of chest, abdomen and pelvis, and a questionnaire.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Clinicopathological diagnosis of Waldenstrom's macroglobulinemia
Measurable disease, defined as presence of immunoglobulin M (IgM) paraprotein with a minimum IgM level of > 2 times the upper limit of each institution's normal value
Slowly progressing disease not requiring therapy for at least 3-6 months
ECOG performance status 0,1 or 2
Total bilirubin < 2 x ULN
SGOT < 3 x ULN
Creatinine < 2 x ULN
Pregnant or breast-feeding women
Patients who are using organic nitrates or alpha-blockers
Grade III/IV cardiac problems
Resting hypotension (BP < 90/50) or hypertension (BP > 170/110)
Cardiac failure or coronary artery disease causing unstable angina